On August 11, 2026, a new Phase 4 clinical trial update was recorded for a study involving insulin detemir. The trial, registered as NCT07112339, is titled "A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes." The study is currently listed with a status of recruiting. It is designated as a Phase 4 trial, meaning it involves further evaluation of an already approved therapy. The trial compares weekly insulin icodec against daily basal insulins, a category that includes insulin detemir, in adults with type 2 diabetes. No results have been posted for this trial at this stage. The event data does not include information on outcomes, efficacy, or safety findings. Details on trial design, comparator arms, and endpoints beyond the study title are not provided in this update. Readers seeking further background on insulin detemir can consult the compound overview for additional context.
Phase 4 Trial Comparing Weekly Icodec to Daily Basal Insulins Recruiting
See the full insulin detemir overview
Source: https://clinicaltrials.gov/study/NCT07112339